AR and neoplasm: After 20–28 d of treatment, 1ae modestly but significantly reduced tumor volumes in both the LNCaP and LNCaP95-D3 xenograft models compared with control animals (Fig. 6i,j): in the AR-V7-driven LNCaP95-D3 xenograft model of CRPC, 1ae outperformed enzalutamide, a second-generation antiandrogen that targets the AR LBD.